Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMaroto, P.
dc.contributor.authorPorta, Camillo
dc.contributor.authorCapdevila Castillon, Jaume
dc.contributor.authorApolo, Andrea B.
dc.contributor.authorViteri Ramirez, Santiago
dc.contributor.authorRodriguez-Antona, Cristina
dc.contributor.authorMartin, Lidia
dc.contributor.authorCastellano, D.
dc.date.accessioned2022-09-19T10:43:00Z
dc.date.available2022-09-19T10:43:00Z
dc.date.issued2022-07-13
dc.identifier.citationMaroto P, Porta C, Capdevila J, Apolo AB, Viteri S, Rodriguez-Antona C, et al. Cabozantinib for the treatment of solid tumors: a systematic review. Ther Adv Med Oncol. 2022 Jul 13;14:1–28.
dc.identifier.issn1758-8359
dc.identifier.urihttp://hdl.handle.net/11351/8216
dc.descriptionCabozantinib; Hepatocellular carcinoma; Solid tumor
dc.description.abstractBackground: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence and the real-world performance of cabozantinib compared with clinical trial data, we performed a systematic review of cabozantinib monotherapy as treatment for solid tumors in adults. Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and registered with PROSPERO (CRD42020144680). We searched for clinical and observational studies of cabozantinib monotherapy for solid tumors using Embase, MEDLINE, and Cochrane databases (October 2020), and screened relevant congress abstracts. Eligible studies reported clinical or safety outcomes, or biomarker data. Small studies (n < 25) and studies of cabozantinib combination therapies were excluded. Quality was assessed using National Institute for Health and Care Excellence methodology, and study characteristics were described qualitatively. Results: Of 2888 citations, 114 were included (52 randomized studies, 29 observational studies, 32 nonrandomized phase I or II studies or pilot trials, and 1 analysis of data from a randomized study and a nonrandomized study). Beyond approved indications, other tumors studied were castration-resistant prostate cancer, urothelial carcinoma, Ewing sarcoma, osteosarcoma, uveal melanoma, non-small-cell lung cancer, Merkel cell carcinoma, glioblastoma, pheochromocytomas and paragangliomas, cholangiocarcinoma, gastrointestinal stromal tumor, colorectal cancer, salivary gland cancer, carcinoid and pancreatic neuroendocrine tumors, and breast, endometrial and ovarian cancers. The most common adverse events were hypertension, diarrhea, and fatigue. Conclusion: The identified evidence demonstrates the positive efficacy/effectiveness of cabozantinib monotherapy in various solid tumor types, with safety findings being consistent with those observed with other VEGFR-targeting tyrosine kinase inhibitors. When available, real-world findings were consistent with the data reported from clinical trials. A limitation of this review is the high proportion of abstracts; however, this allowed us to capture the most up-to-date findings.
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofseriesTherapeutic Advances in Medical Oncology;14
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectCàncer - Tractament
dc.subjectProteïnes quinases - Inhibidors - Ús terapèutic
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshProtein-Tyrosine Kinases
dc.subject.mesh/antagonists & inhibitors
dc.subject.meshNeoplasms
dc.subject.mesh/drug therapy
dc.titleCabozantinib for the treatment of solid tumors: a systematic review
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1177/17588359221107112
dc.subject.decsproteína-tirosina cinasas
dc.subject.decs/antagonistas & inhibidores
dc.subject.decsneoplasias
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://doi.org/10.1177/17588359221107
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Maroto P] Medical Oncology Services, Hospital de la Santa Creu i Sant Pau, Mas Casanovas, Barcelona, 08025, Spain. [Porta C] Interdisciplinary Department of Medicine, University of Bari “Aldo Moro,” Bari, Italy. [Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Apolo AB] Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. [Viteri S] UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain. [Rodriguez-Antona C] Antona National Cancer Research Center, Madrid, Spain. [Martin L] Ipsen Pharma, Barcelona, Spain. [Castellano D] Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
dc.identifier.pmid35847482
dc.identifier.wos000827721700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record